SCHEMBL1007296

SCHEMBL1007296

COC(=O)c1scc([N+](=O)[O-])c1NC(C)=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.50
ALDH1A1 P00352 4/20 0.45
MAPT P10636 3/20 0.44
PKM P14618 1/20 0.44
ATM Q13315 1/20 0.44
POLB P06746 3/20 0.41
CYP1A2 P05177 2/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2C19 P33261 1/20 0.41
HTR1A P08908 1/20 0.40
SCN1A P35498 1/20 0.40
SCN2A Q99250 1/20 0.40
SCN3A Q9NY46 1/20 0.40
GALR2 O43603 1/20 0.40
MITF O75030 1/20 0.40
LMNA P02545 1/20 0.40
HSP90AA1 P07900 1/20 0.40
HPGD P15428 1/20 0.40
XBP1 P17861 1/20 0.40
CCR6 P51684 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27894129 0.85 ALDH1A1 (0.47) KMT2AALDH1A1MAPTPKMPOLB
SCHEMBL23012362 0.80 MAPT (0.64) KMT2AALDH1A1MAPTPKMATM
SCHEMBL13545969 0.78 ALDH1A1 (0.49) KMT2AALDH1A1MAPTPKMATM
SCHEMBL28290128 0.77 ALDH1A1 (0.48) KMT2AALDH1A1MAPTPOLBLMNA
SCHEMBL2953619 0.75 KMT2A (0.48) KMT2AALDH1A1MAPTPKMATM
SCHEMBL1005344 0.75 KMT2A (0.48) KMT2AALDH1A1MAPTPKMATM
SCHEMBL30898855 0.75 KMT2A (0.42) KMT2AALDH1A1MAPTPKMCYP1A2
SCHEMBL13545970 0.73 ALDH1A1 (0.42) KMT2AALDH1A1LMNASMN1; SMN2SLC10A6
SCHEMBL23412611 0.73 MAPT (0.40) KMT2AALDH1A1MAPTPOLBGALR2
SCHEMBL31411579 0.72 PDGFRB (0.48) KMT2AALDH1A1MAPTPOLBCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118236-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-19 US disclosed
EP-2269990-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-01-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118236-A1 HETEROCYCLIC COMPOUND GRIN1, GRM1, GRIK1 KMT2A 1139/4885ALDH1A1 614/4885MAPT 4623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.